Pretax income is the income that a company earns before paying income taxes. Regulus Therapeutics's pretax income for the
three
months ended in Dec. 2024 was $-12.79 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-46.36 Mil.
Regulus Therapeutics's pretax margin was %.
During the past 13 years, Regulus Therapeutics's highest Pretax Margin was -157.21%. The lowest was -100141.67%. And the median was -3563.20%.
Regulus Therapeutics Pre-Tax Income Historical Data
The historical data trend for Regulus Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regulus Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Regulus Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regulus Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Regulus Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regulus Therapeutics (NAS:RGLS) Pre-Tax Income Explanation
Regulus Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Regulus Therapeutics's highest Pretax Margin was -157.21%. The lowest was -100141.67%. And the median was -3563.20%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regulus Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Regulus Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGLS has been successfully added to your 